Top Markets
#1 DogBull DogBull +105.02%
#2 Siacoin Siacoin +53.82%
#3 UnifAI Network UnifAI Network +49.44%
#4 MarsCoin MarsCoin +49.07%
#5 ADO Protocol ADO Protocol +46.44%
#6 Ontology Gas Ontology Gas +25.91%
#7 Magma Finance Magma Finance +21.20%
#8 Useless Coin Useless Coin +21.16%
#9 Cash Cat Cash Cat +16.86%
#10 Apertum Apertum +13.60%
Coin of the day
DogBull DogBull
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Newron Pharmaceuticals S.p.A. Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A.

NP5
Classifica tra le azioni #15968
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in... Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
Prezzo delle azioni
$15.42
Capitalizzazione di mercato
$320.83M
Variazione (1 giorno)
-1.52%
Variazione (1 anno)
40.67%
Paese
IT
Scambia Newron Pharmaceuticals S.p.A. (NP5)

Categoria

Healthcare
Ricavi di Newron Pharmaceuticals S.p.A. (NP5)
Ricavi nel Sep 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Newron Pharmaceuticals S.p.A., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Newron Pharmaceuticals S.p.A. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH